Anxiety Disorders Therapeutics
1. Cymbalta patent expiration
Treatment: Management of fibromyalgia (fm); Method of treating anxiety
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
|
US6596756 (Pediatric) | LILLY | Treatment of fibromyalgia |
Mar, 2020
(5 years ago) | |
| US5508276 | LILLY | Duloxetine enteric pellets |
Jul, 2014
(11 years ago) | |
| US6596756 | LILLY | Treatment of fibromyalgia |
Sep, 2019
(6 years ago) | |
| US5023269 | LILLY | 3-aryloxy-3-substituted propanamines |
Jun, 2013
(12 years ago) | |
|
US5023269 (Pediatric) | LILLY | 3-aryloxy-3-substituted propanamines |
Dec, 2013
(12 years ago) | |
|
US5508276 (Pediatric) | LILLY | Duloxetine enteric pellets |
Jan, 2015
(10 years ago) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Indication(I-617) | Nov 19, 2012 |
| New Indication(I-632) | Nov 04, 2013 |
| Pediatric Exclusivity(PED) | Apr 18, 2016 |
| M(M-61) | Oct 18, 2015 |
| New Patient Population(NPP) | Apr 20, 2023 |
Drugs and Companies using DULOXETINE HYDROCHLORIDE ingredient
Market Authorisation Date: 03 August, 2004
Dosage: CAPSULE, DELAYED REL PELLETS
How can I launch a generic of CYMBALTA before it's drug patent expiration?
More Information on Dosage
CYMBALTA family patents
2. Lyrica patent expiration
Treatment: Management of fibromyalgia; Treatment of seizure disorder; Treatment of pain, including neuropathic pain associated with diabetic peripheral neuropathy or spinal cord injury, postherpetic neuralgia, a...
LYRICA IPR and PTAB Proceedings
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US6197819 | UPJOHN | Gamma amino butyric acid analogs and optical isomers |
Dec, 2018
(7 years ago) | |
| US6001876 | UPJOHN | Isobutylgaba and its derivatives for the treatment of pain |
Dec, 2018
(7 years ago) | |
|
US6001876 (Pediatric) | UPJOHN | Isobutylgaba and its derivatives for the treatment of pain |
Jun, 2019
(6 years ago) | |
| US5563175 | UPJOHN | GABA and L-glutamic acid analogs for antiseizure treatment |
Oct, 2013
(12 years ago) | |
|
US6197819 (Pediatric) | UPJOHN | Gamma amino butyric acid analogs and optical isomers |
Jun, 2019
(6 years ago) | |
|
USRE41920 (Pediatric) | UPJOHN | Isobutylgaba and its derivatives for the treatment of pain |
Jun, 2019
(6 years ago) | |
| USRE41920 | UPJOHN | Isobutylgaba and its derivatives for the treatment of pain |
Dec, 2018
(7 years ago) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Indication(I-651) | Jun 20, 2015 |
| M(M-193) | Dec 22, 2019 |
| New Patient Population(NPP) | May 23, 2022 |
| Pediatric Exclusivity(PED) | Nov 23, 2022 |
Drugs and Companies using PREGABALIN ingredient
Market Authorisation Date: 30 December, 2004
Dosage: CAPSULE; SOLUTION
How can I launch a generic of LYRICA before it's drug patent expiration?
More Information on Dosage
LYRICA family patents